Clinical trial
Long-term Study Of Ropinirole In Restless Legs Syndrome
NCT00329602 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00329602 |
|---|---|
| Title | Long-term Study Of Ropinirole In Restless Legs Syndrome |
| Official title | A Parallel Group Study to Evaluate the Efficacy and Safety of Ropinirole for 26 Weeks and to Further Evaluate the Incidence of Augmentation and Rebound for a Further 40 Weeks Open-label Extension Treatment Period in Subjects Suffering From Moderate to Severe Restless Legs Syndrome. |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Restless Legs Syndrome |
| Intervention type | Drug |
| Interventions | Placebo, Ropinirole |
| Enrollment | 404 |
| Start date | Mar 1, 2006 |
| Primary completion | Sep 1, 2008 |
| Completion | Sep 1, 2008 |
| First posted | May 25, 2006 |
| Last update posted | Mar 23, 2017 |
| Countries | Australia, Czechia, Denmark, Germany, Italy, Norway, Portugal, Slovakia, Spain, Sweden, Switzerland |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: